Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [RNA-Seq]

ABSTRACT: Graphene Oxide Antigen Presenting Platform was designed for human T cell activation superior to commercial beads. We used deep RNA sequencing to study the mechanism of the T cell activation from PBMCs.

ORGANISM(S): Homo sapiens

PROVIDER: GSE233259 | GEO | 2024/07/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [scRNA-Seq]

Project description:Graphene Oxide Antigen Presenting Platform was designed for human T cell activation superior to commercial beads. We used single cell RNA sequencing (scRNA-seq) to study the genome-wide transcriptome profiling of the activated T cells from PBMCs.

2024-07-01 | GSE233290 | GEO

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-07-01 | GSE233291 | GEO

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies

Project description:Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies

| PRJNA975812 | ENA

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [RNA-Seq]

Project description:Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [RNA-Seq]

| PRJNA975578 | ENA

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [scRNA-Seq]

Project description:Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [scRNA-Seq]

| PRJNA976061 | ENA

A transcriptomic overview of lung and liver changes one day after pulmonary exposure to graphene and graphene oxide

Project description:This study investigates transcriptomic differences in the lung and liver after pulmonary exposure to two Graphene based materials with similar physical properties, but different surface chemistry. Female C57BL/6 mouse were exposed by a single intratracheal instillation of 0, 18, 54 or 162 μg/mouse of graphene oxide (GO) or reduced graphene oxide (rGO). Pulmonary and hepatic transcriptional changes were compared to identify commonly and uniquely perturbed functions and pathways by GO and rGO. These changes were then related to previously analyzed endpoints. GO exposure induced more differentially expressed genes, affected more functions, and perturbed more pathways compared to rGO, both in the lung and liver.

2020-10-21 | GSE159707 | GEO

Methylation arrays (MethylationEPIC) of human lung epithelial BEAS-2B cells exposed to reduced graphene oxide

Project description:Nanomaterials have lots of promising applications, and concern has risen about their impact to human health. Here, we have analyzed the genome-wide DNA methylation changes associated to the exposure to reduced graphene oxide (rGO) in human lung epithelial cells. Six conditions were assayed, with two technical replicates per condition (12 arrays in total): control, 1 and 10 µg/mL of rGO for 15 or 30 days of exposure.

2019-09-16 | E-MTAB-7719 | biostudies-arrayexpress

Identification of protein corona on graphene oxide in B medium

Project description:As antimicrobials, graphene materials (GMs) may have advantages over traditional antibiotics due to their physical mechanisms of action which ensure less chance of development of microbial resistance. However, the fundamental question as to whether the antibacterial mechanism of GMs originates from penetration by their sharp edges or wrapping of the cell membrane, or from a combination of these and other mechanisms, remains controversial. In this study, we show both experimentally and theoretically that GMs with high surface oxygen content (SOC) predominantly attach in parallel to the bacterial cell surface when in the suspension phase. The interaction mode shifts to perpendicular interaction when the SOC reaches a threshold of ~ 0.3 (the atomic percent of O in the total atoms). However, neither mode necessarily kills bacteria. Rather, bactericidal activity depends on the interaction of GMs with surrounding biomolecules. Proteomic study shows that protein corona forms on the surface graphene oxide in LB medium, thus explain the different antibacterial activity in different culture medium.

2023-05-10 | PXD027909 | Pride

Microbes in sewage treated with graphene oxide

Project description:Microbes in sewage treated with graphene oxide Raw sequence reads

| PRJNA873880 | ENA

Graphene Oxide Substrate Promotes Neurotrophic Factor Secretion and Survival of Human Schwann-Like Adipose Mesenchymal Stromal Cells - RNAseq

Project description:Mesenchymal stromal cells from adipose tissue (AD-MSCs) exhibit favourable clinical traits for autologous transplantation and can develop a ‘Schwann-like’ phenotype (sAD-MSCs) to improve peripheral nerve regeneration, where severe injuries yield insufficient recovery. However, sAD-MSCs regress without biochemical stimulation and detach from conduits under unfavourable transplant conditions, negating their paracrine effects. Graphene-derived materials support AD-MSC attachment, regulating cell adhesion and function through physiochemistry and topography. We report graphene oxide (GO) as a suitable substrate for human sAD-MSCs incubation towards severe peripheral nerve injuries, through evaluating transcriptome changes, neurotrophic factor expression over a 7-day period, and cell viability in apoptotic conditions. Transcriptome changes from GO incubation across four patients were minor compared to biological variance.

2021-03-08 | E-MTAB-10078 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data